Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing.
RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with previously
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
Travis Lakins - MLB Trade Rumors mlbtraderumors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mlbtraderumors.com Daily Mail and Mail on Sunday newspapers.
Brandon Waddell - MLB Trade Rumors mlbtraderumors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mlbtraderumors.com Daily Mail and Mail on Sunday newspapers.